Biohaven’s high-risk bet

Investors who thought last year’s failure in Alzheimer’s had spelled the end of Biohaven’s troriluzole might be surprised to learn that the project is still in play. Phase 3 data are due before mid year in a different neurodegenerative disorder, spinocerebellar ataxia.